-
Mashup Score: 36
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Source: guoncologynow.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 79Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043 - 3 month(s) ago
Epigenetic modulation is well established in hematologic malignancies but to a lesser degree in solid tumors. Here we report the results of a phase Ib/II study of guadecitabine and durvalumab in advanced clear cell renal cell carcinoma (ccRCC; NCT03308396). Patients received guadecitabine (starting at 60 mg/m2 subcutaneously on days 1-5 with de-escalation to 45 mg/m2 in case of dose limiting…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Thrilled to share our clinical trial conducted though @BigTenCRC in @NatureComms combining hypomethylating agent guadecitabine and IO in ccRCC. Huge team effort in conducting and publishing this IIT. https://t.co/CXjnopsBQ7 @AlvaAjjai @eric_facs @MonikaJoshimd @RohanGarjeMD
-
-
Mashup Score: 0ASCO - 8 month(s) ago
Dear Colleagues,Many physicians have raised concerns about the current Maintenance of Certification (MOC) requirements administered by the American Board of Internal Medicine (ABIM). ASCO members are no exception, and we have heard widespread concern that the program, including the current Longitudinal Knowledge Assessment, is not supporting relevant learning and can be time-consuming and…
Source: m.email.asco.orgCategories: Latest Headlines, Oncologists2Tweet-
Great initiative @ASCO . Thank you for hearing your members concerns!! @CliffordHudis @ASCOPres #proudmember https://t.co/bhounPtERE
-
-
Mashup Score: 11Dr. Yousef Zakharia: "I Believe in Teamwork" - 8 month(s) ago
Dr. Yousef Nabih Zakharia’s journey from Syria to the heart of Iowa, his dedication to his patients, and his unwavering commitment to advancing kidney cancer research is truly inspiring.
Source: kidneycan.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Very honored and humbled by @kidneycan spotlight, a great community to be part of. @UIowaCancer @uihealthcare @IntMedatIowa @IowaMed @UIowa_urology Dr. Yousef Zakharia | KidneyCAN Community Spotlight https://t.co/RoaT6tsZmR
-
-
Mashup Score: 8The world’s platform for change - 9 month(s) ago
Change.org is the world’s largest petition platform, using technology to empower more than 200 million users to create the change they want to see.
Source: www.change.orgCategories: Expert Picks, Latest HeadlinesTweet-
Over 15,000 of you have signed the petition to #EndMOC Sign and join the chorus of voices to stop the monopoly & restore our autonomy They are counting on your silence Petition · Eliminate ABIMs MOC requirement · https://t.co/VSMDouPesd https://t.co/3MsbW8XjIE
-
With more than 15k sig over 3 weeks, we certainly hope @ABIMcert and @RichardBaron17 would listen and intervene! @chadinabhan @AaronGoodman33 Petition · Eliminate ABIMs MOC requirement · https://t.co/5IW2VnTQUw https://t.co/W2ztdNd4ii
-
-
Mashup Score: 0Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial - 10 month(s) ago
Abstract. Purpose: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading to more robust immune responses. Increased anti-tumor T-cell responses may confer increased anti-tumor activity in patients with…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial @MelanomaIowa @UIowaCancer @IntMedatIowa @uihealthcare https://t.co/BSLaUCyeUJ
-
-
Mashup Score: 2Practice Changing Topics - How the Experts Treat With Dr. Chandler Park Featuring Yousef Zakharia, MD - 1 year(s) ago
Practice Changing Topics – How the Experts Treat With Dr. Chandler Park Featuring Yousef Zakharia, MD
Source: VuMediCategories: Latest Headlines, Oncologists2Tweet-
RT @SteveWi27717554: Goosebump evoking stuff from @ZakhariaYousef with @CParkMD https://t.co/4Puz8FMWfp
-
-
Mashup Score: 0Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study). - 2 year(s) ago
503 Background: Metastatic urothelial cancer is aggressive and associated with dismal 5-yr overall survival. Platinum-based chemotherapy and checkpoint inhibitors are standard first-line options with enfortumab vedotin, sacituzumab govitecan, and erdafitinib (in select FGFR altered tumors) subsequently utilized upon disease progression. However, despite these options, long-term outcomes remain…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Avelumab Docetaxol IIT @UIowaCancer with encouraging result https://t.co/a7KfAqj8e4 @RohanGarjeMD @VigneshPackiam @uihealthcare @IntMedatIowa @UIowa_urology https://t.co/VJHh5FLDQx
-
-
Mashup Score: 02022 IKCS: North America - Kidney Cancer Association Symposium - 2 year(s) ago
Join the Kidney Cancer Association for the 2022 International Kidney Cancer Symposium: Europe, a hybrid event April 22-24, 2022.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to a successful #IKCSNA22 this November in Austin, Texas! Register now and join us. https://t.co/P3Q4vqCna8 @KidneyCancer https://t.co/NCVAdtgvQK
-
-
Mashup Score: 6Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC - 2 year(s) ago
Vignesh Packiam, MD, explains how innovation driven by the BCG shortage led to a potential promising new regimen of sequential intravesical gemcitabine and docetaxel for patients with BCG-naïve non–muscle-invasive bladder cancer.
Source: Urology TimesCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @UrologyTimes: Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC https://t.co/apmcafulM9 #urology #…
-
Thank you @GUOncologyNow for highlighting our recent @NatureComms paper IIT through @BigTenCRC @AlvaAjjai @eric_facs @MonikaJoshimd @RohanGarjeMD @UIowaCancer @IntMedatIowa Epigenetic Regulation for Immune Evasion in Advanced Kidney Cancer https://t.co/u5pXgghi66